标题/作者	年份
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact F Cantini, L Niccoli, D Matarrese, E Nicastri, P Stobbione, D Goletti Journal of Infection 81 (2), 318-356	2020
Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis SR Ytterberg, DL Bhatt, TR Mikuls, GG Koch, R Fleischmann, JL Rivas, ... New England Journal of Medicine 386 (4), 316-326	2022
Natural history of COVID-19 and current knowledge on treatment therapeutic options WG Dos Santos Biomedicine & Pharmacotherapy 129, 110493	2020
Baricitinib restrains the immune dysregulation in patients with severe COVID-19 V Bronte, S Ugel, E Tinazzi, A Vella, F De Sanctis, S Canè, V Batani, ... The Journal of clinical investigation 130 (12), 6409-6416	2020
Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19 W Luo, YX Li, LJ Jiang, Q Chen, T Wang, DW Ye Trends in pharmacological sciences 41 (8), 531-543	2020
Abrocitinib versus placebo or dupilumab for atopic dermatitis T Bieber, EL Simpson, JI Silverberg, D Thaçi, C Paul, AE Pink, Y Kataoka, ... New England Journal of Medicine 384 (12), 1101-1112	2021
COVID-19 revisiting inflammatory pathways of arthritis G Schett, B Manger, D Simon, R Caporali Nature Reviews Rheumatology 16 (8), 465-470	2020
Immunomodulation in COVID-19 NE Ingraham, S Lotfi-Emran, BK Thielen, K Techar, RS Morris, SG Holtan, ... The Lancet Respiratory Medicine 8 (6), 544-546	2020
Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series V Furer, D Zisman, A Kibari, D Rimar, Y Paran, O Elkayam Rheumatology 60 (SI), SI90-SI95	2021
The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19 C Perricone, P Triggianese, E Bartoloni, G Cafaro, AF Bonifacio, R Bursi, ... Journal of Autoimmunity 111, 102468	2020
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach Y Tanaka, Y Luo, JJ O’Shea, S Nakayamada Nature Reviews Rheumatology 18 (3), 133-145	2022
COVID‐19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease‐modifying antirheumatic drugs on clinical outcomes RH Haberman, R Castillo, A Chen, D Yan, D Ramirez, V Sekar, R Lesser, ... Arthritis & Rheumatology 72 (12), 1981-1989	2020
COVID‐19 and immunological regulations–from basic and translational aspects to clinical implications MP Schön, C Berking, T Biedermann, T Buhl, L Erpenbeck, K Eyerich, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18 (8), 795-807	2020
Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis F Wang, L Sun, S Wang, JM Davis III, EL Matteson, MH Murad, F Luo, ... Mayo Clinic Proceedings 95 (7), 1404-1419	2020
JAK inhibitors and infections risk: focus on herpes zoster F Sunzini, I McInnes, S Siebert Therapeutic Advances in Musculoskeletal Disease 12, 1759720X20936059	2020
Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients DE Dulek, RC Fuhlbrigge, AC Tribble, JA Connelly, MM Loi, H El Chebib, ... Journal of the Pediatric Infectious Diseases Society 9 (6), 716-737	2020
Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic E Price, E MacPhie, L Kay, P Lanyon, B Griffiths, C Holroyd, A Abhishek, ... Clinical Medicine 20 (3), 256	2020
Translating JAKs to jakinibs M Gadina, DA Chisolm, RL Philips, IB McInness, PS Changelian, ... The Journal of Immunology 204 (8), 2011-2020	2020
Refractory sarcoidosis: a review T El Jammal, Y Jamilloux, M Gerfaud-Valentin, D Valeyre, P Sève Therapeutics and Clinical Risk Management, 323-345	2020
JAK inhibitors safety in ulcerative colitis: practical implications M Agrawal, ES Kim, JF Colombel Journal of Crohn's and Colitis 14 (Supplement_2), S755-S760	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。